ALNY monthly performance report
Monthly ALNY research: returns, drawdown, relative strength, seasonality, and key stats.
ALNY monthly report
—
Key takeaways
- Alnylam Pharmaceuticals (ALNY) closed August 2026 at $228.72, up 11.29% for the month and −45.40% over the trailing 12 months.
- Year-to-date, ALNY is −42.48%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading −34.12% versus its 200-day moving average ($347.17), a cautious technical signal.
- Over the past three years, ALNY has underperformed the S&P 500 by −49.04%, with a relative strength index reading of 72.7.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 19 negative months.
Alnylam Pharmaceuticals ended August 2026 at $228.72, posting a monthly return of +11.29%. The S&P 500 returned +3.05% over the same window, leaving relative performance at +8.24%.
The current quarter stands at −30.31% (Q3 2026 (QTD)), while medium-term trend remains soft: price is −34.12% versus the 200-day moving average ($347.17).
Year-to-date, ALNY is −42.48% against SPY +12.89%, a gap of −55.37%. The stock is currently −53.85% below its 52-week high, with maximum 3-year drawdown at −58.17%.
| Period | ALNY | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +4.44% | −0.20% | +4.64% |
| 1 Week | −20.70% | +3.90% | −24.60% |
| 1 Month | +11.29% | +3.05% | +8.24% |
| 3 Months | −26.10% | +7.11% | −33.21% |